Corneal neovessels
Conditions
Interventions
Trade Name: Lucentis®
Product Name: Ranibizumab(Lucentis®)
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Ranibizumab
Sponsors
University of Nottingham
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with all the below criteria: - Patients over the age of 18 - With corneal neovascularisation non responsive or non tolerant to conventional steroid therapy - And capable of consenting Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - Patients under 18 years of age - Patients unable to provide informed consent - Patients who are needle phobic - Patients refusing consent - Pregnant women or women aiming for conception - Patients with communication difficulties - Patients with hypersensitivity to the active substance or to any of the excipients. - Patients with active or suspected ocular or periocular infections. - Patients with active severe intraocular inflammation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the use of the drug in the treatment of active corneal new blood vessels.; Secondary Objective: To determine whether established corneal vessels too would be influenced to a limited extent with lucentis and whether there is any gain in visual acuity following ‘regression’ of corneal new vessels. (regressed vessels remain as fine white lines ‘ghost vessels’ that no longer carry blood). ;Primary end point(s): Decreased corneal neovascularisation | — |
Countries
United Kingdom
Outcome results
None listed